Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$22.80 USD
+0.59 (2.66%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $22.80 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum C VGM
Income Statements
Fiscal Year end for Corcept Therapeutics Incorporated falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 482 | 402 | 366 | 354 | 306 |
Cost Of Goods | 6 | 5 | 5 | 6 | 6 |
Gross Profit | 476 | 396 | 361 | 348 | 301 |
Selling & Adminstrative & Depr. & Amort Expenses | 369 | 284 | 236 | 220 | 189 |
Income After Depreciation & Amortization | 107 | 113 | 124 | 128 | 112 |
Non-Operating Income | 17 | 4 | 1 | 3 | 5 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 125 | 116 | 125 | 132 | 117 |
Income Taxes | 18 | 15 | 12 | 26 | 23 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 106 | 101 | 113 | 106 | 94 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 106 | 101 | 113 | 106 | 94 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 101 | 116 | 128 | 132 | 114 |
Depreciation & Amortization (Cash Flow) | -7 | 3 | 3 | 4 | 2 |
Income After Depreciation & Amortization | 107 | 113 | 124 | 128 | 112 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 111.74 | 115.97 | 125.96 | 124.19 | 122.57 |
Diluted EPS Before Non-Recurring Items | 0.94 | 0.87 | 0.89 | 0.85 | 0.77 |
Diluted Net EPS (GAAP) | 0.94 | 0.87 | 0.89 | 0.85 | 0.77 |
Fiscal Year end for Corcept Therapeutics Incorporated falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 135.41 | 123.60 | 117.72 | 105.65 |
Cost Of Goods | NA | 1.88 | 1.65 | 1.57 | 1.39 |
Gross Profit | NA | 133.53 | 121.96 | 116.14 | 104.27 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 101.86 | 90.78 | 86.56 | 89.41 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 31.67 | 31.18 | 29.58 | 14.86 |
Non-Operating Income | NA | 5.14 | 5.21 | 3.35 | 3.58 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | 36.81 | 36.39 | 32.93 | 18.43 |
Income Taxes | NA | 5.45 | 5.01 | 5.40 | 2.56 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 31.36 | 31.38 | 27.53 | 15.88 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 31.36 | 31.38 | 27.53 | 15.88 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 110.89 | 111.10 | 109.59 | 115.43 |
Diluted EPS Before Non-Recurring Items | NA | 0.28 | 0.28 | 0.25 | 0.14 |
Diluted Net EPS (GAAP) | NA | 0.27 | 0.28 | 0.25 | 0.14 |